The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.

Preclinical animal study assessing the effects of Semax and a derivative peptide on behavior and amyloidosis in transgenic mice.

“The present study assessed the effect of the known neuroprotective peptide Semax and its derivative on the behavioral characteristics and development of amyloidosis in transgenic APPswe/PS1dE9/Blg mice acting as a model of Alzheimer’s disease.”

Male APPswe/PS1dE9/Blg transgenic mice and wild-type C57Bl6/Chg mice.

“The experiments were conducted using 60 male APPswe/PS1dE9/Blg (APP/PS1) mice with a mixed C57Bl6/Chg genetic background and 20 male C57Bl6/Chg (wild-type, WT) mice.”

Both Semax and its derivative improved cognitive functions in mice as demonstrated by open field, novel object recognition, and Barnes maze tests.

“The open field, novel object recognition, and Barnes maze tests demonstrated that both Semax and its derivative improved cognitive functions in mice.”

Histological examination showed that the peptides reduced the number of amyloid inclusions in the cortex and hippocampus.

“Histological examination showed that these peptides reduced the number of amyloid inclusions in the cortex and hippocampus of the animals’ brains.”